{"filing":{"accession_number":"0000875045-26-000073","cik":"0000875045","ticker":"BIIB","company_name":"BIOGEN INC.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"biib-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/biib-20260729.htm"},"events":[{"id":21315,"run_id":19218,"accession_number":"0000875045-26-000073","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Biogen issued a press release on July 29, 2026 announcing its second quarter 2026 financial results, including total revenue of $2.7 billion (up 3% year-over-year), GAAP diluted EPS of $0.66, and Non-GAAP diluted EPS of $3.60. The disclosure includes detailed revenue breakdowns by product and segment, expense summaries, cash flow information, and updated full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02 of Form 8-K.","company_name":"BIOGEN INC.","ticker":"BIIB","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":20931,"accession_number":"0000875045-26-000073","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Biogen issued a press release on July 29, 2026 announcing its second quarter 2026 financial results, including total revenue of $2.7 billion (up 3% year-over-year), GAAP diluted EPS of $0.66, and Non-GAAP diluted EPS of $3.60. The disclosure includes detailed revenue breakdowns by product and segment, expense summaries, cash flow information, and updated full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02 of Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:14:23.417485+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20931,"accession_number":"0000875045-26-000073","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Biogen issued a press release on July 29, 2026 announcing its second quarter 2026 financial results, including total revenue of $2.7 billion (up 3% year-over-year), GAAP diluted EPS of $0.66, and Non-GAAP diluted EPS of $3.60. The disclosure includes detailed revenue breakdowns by product and segment, expense summaries, cash flow information, and updated full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02 of Form 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:14:23.417485+00:00","company_name":"BIOGEN INC.","ticker":"BIIB","filing_date":"2026-07-29"}]}